ALC — Alcon Inc.

Summary of Alcon's Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Sales: Q1 sales reached $2.7 billion, a 6% increase year-over-year.
• Surgical Franchise: Revenue was $1.5 billion, up 6%. Implantable sales were $438 million (1% growth), while consumables grew 4% to $769 million. Equipment sales surged 23% to $253 million, driven by Unity product momentum.
• Vision Care: Sales were $1.2 billion, also up 6%. Contact lens sales increased 4% to $738 million, with growth attributed to product innovation and price increases. Ocular health sales rose 10% to $487 million, led by dry eye products.
• Margins: Core gross margin was 63%, down 40 basis points year-over-year, primarily due to tariff impacts. Core operating margin remained flat at 21.2%.
• Earnings: Core diluted earnings per share were $0.85. Free cash flow was $279 million, flat compared to the previous year.
• Tariffs: Incremental tariff-related charges were $33 million in Q1, with an updated assumption of a 10% average tariff rate for the remainder of the year.

2. Strategic Updates and Business Highlights

• Product Innovation: Alcon launched several new products, including the Unity VCS surgical device, PanOptix Pro trifocal IOL, and True Plus enhanced monofocal IOL, which are gaining market traction.
• Market Share Gains: The company reported share gains in U.S. AT-IOLs, surgical equipment, consumables, contact lenses, and dry eye products.
• AI Integration: Alcon is leveraging AI to enhance productivity and decision-making across R&D, operations, and commercial functions.
• Operational Improvements: The company is focused on scaling innovation and improving operational efficiencies.

3. Forward Guidance and Outlook

• Market Growth: Alcon expects aggregate eye care markets to grow 3% to 4% in 2026, with constant currency sales growth projected between 5% and 7%.
• Margin Expansion: Core operating margin is expected to expand by 70 to 170 basis points, with most growth anticipated in the second half of the year.
• EPS Growth: Core diluted EPS is projected to grow between 10% and 13%.
• Share Repurchase Program: A new $1.5 billion share repurchase program was approved, reflecting strong cash flow generation.

4. Bad News, Challenges, or Points of Concern

• Market Conditions: The surgical market, particularly for cataracts, remains soft, with low single-digit growth in global procedure volumes. The company noted ongoing competitive pressures, especially in the implantable category.
• China Market Weakness: Alcon experienced pressure in the Chinese market, which negatively impacted overall performance.
• Tariff Pressures: Although the company reduced its tariff expense outlook, it still faced significant costs that impacted margins.
• Competitive Landscape: Heightened competition in the IOL market, particularly in international markets, poses risks to market share.

5. Notable Q&A Insights

• Implantable Growth: Management acknowledged that surgical glaucoma pressures and supply issues (specifically with Hydrus) impacted growth. However, core growth in the U.S. was noted to be stronger when excluding these factors.
• Market Confidence: Despite recent softness, management expressed confidence in the long-term demand for cataract surgeries and the potential for market recovery as healthcare systems adapt.
• Contact Lens Dynamics: The company is gaining share in reusable contact lenses, but faced challenges with DAILIES sales in the U.S. due to legacy product declines.
• Tryptyr Performance: Strong refill rates and expanding prescriber base were highlighted as key growth drivers for the dry eye product Tryptyr.
• M&A Strategy: Alcon remains focused on smaller tuck-in acquisitions, with no significant changes to its M&A strategy despite recent deal exits.

Overall, Alcon's Q1 2026 performance showcased solid growth driven by innovation and market share gains, although challenges in specific markets and competitive pressures remain areas of concern. The company maintains a positive outlook for the remainder of the year, supported by a robust product pipeline and operational improvements.